Cizumab is a DCGI-approved Bevacizumab biosimilar injection widely used in the management of several solid tumors. It contains bevacizumab 400 mg, a monoclonal antibody that plays a crucial role in targeted cancer therapy. Bevacizumab works by inhibiting vascular endothelial growth factor (VEGF), a key protein responsible for the formation of new blood vessels that supply nutrients to tumors. By blocking VEGF, Cizumab helps slow tumor growth and prevents cancer from spreading.

This Bevacizumab biosimilar injection is commonly used in the treatment of colorectal and rectal cancer, ovarian cancer, cervical cancer, kidney (renal cell) cancer, lung cancer, and brain tumors, often in combination with chemotherapy or other anticancer agents. The bevacizumab dose and treatment schedule depend on the type of cancer, patient weight, and overall clinical condition, and it is administered intravenously under medical supervision.

The uses of bevacizumab include improving progression-free survival and enhancing treatment outcomes in advanced or metastatic cancers. Common bevacizumab side effects may include high blood pressure, fatigue, headache, protein in urine, bleeding, delayed wound healing, and gastrointestinal disturbances, though not all patients experience these effects.

Overall, Cizumab offers a cost-effective and clinically proven option for modern cervical, ovarian, colon and rectum, kidney, and brain tumor treatments, supporting better access to advanced cancer care.